Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Humacyte Inc (NASDAQ: HUMA) was $1.61 for the day, down -4.17% from the previous closing price of $1.68. In other words, the price has decreased by -$4.17 from its previous closing price. On the day, 4.24 million shares were traded. HUMA stock price reached its highest trading level at $1.6698 during the session, while it also had its lowest trading level at $1.61.
Ratios:
Our analysis of HUMA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.93 and its Current Ratio is at 2.45. In the meantime, Its Debt-to-Equity ratio is 20.66 whereas as Long-Term Debt/Eq ratio is at 19.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Barclays on August 27, 2025, initiated with a Overweight rating and assigned the stock a target price of $3.50.
H.C. Wainwright reiterated its Buy rating for the stock on December 20, 2024, while the target price for the stock was revised from $12 to $15.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 19 ’25 when Dougan Brady W sold 1,100,000 shares for $1.63 per share. The transaction valued at 1,793,000 led to the insider holds 591,685 shares of the business.
Dougan Brady W sold 549,360 shares of HUMA for $1,005,329 on Aug 18 ’25. The Director now owns 1,691,685 shares after completing the transaction at $1.83 per share. On Aug 20 ’25, another insider, Dougan Brady W, who serves as the Director of the company, sold 591,685 shares for $1.58 each. As a result, the insider received 934,862 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 266843312 and an Enterprise Value of 300911200. For the stock, the TTM Price-to-Sale (P/S) ratio is 311.86 while its Price-to-Book (P/B) ratio in mrq is 62.11. Its current Enterprise Value per Revenue stands at 367.862 whereas that against EBITDA is -2.896.
Stock Price History:
The Beta on a monthly basis for HUMA is 1.88, which has changed by -0.71146953 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $6.77, while it has fallen to a 52-week low of $1.15. The 50-Day Moving Average of the stock is -14.43%, while the 200-Day Moving Average is calculated to be -40.39%.
Shares Statistics:
HUMA traded an average of 4.44M shares per day over the past three months and 4020400 shares per day over the past ten days. A total of 156.34M shares are outstanding, with a floating share count of 131.52M. Insiders hold about 17.20% of the company’s shares, while institutions hold 36.67% stake in the company. Shares short for HUMA as of 1756425600 were 33603019 with a Short Ratio of 7.74, compared to 1753920000 on 31871443. Therefore, it implies a Short% of Shares Outstanding of 33603019 and a Short% of Float of 24.350001.
